Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Medtronic
Harvard Business School
Merck
Dow

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

AEMCOLO Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Aemcolo, and what generic alternatives are available?

Aemcolo is a drug marketed by Cosmo Technologies and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-six patent family members in nineteen countries.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rifamycin profile page.

Summary for AEMCOLO
Drug patent expirations by year for AEMCOLO
Generic Entry Opportunity Date for AEMCOLO
Generic Entry Date for AEMCOLO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, DELAYED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AEMCOLO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Hunter Holmes Mcguire Veteran Affairs Medical CenterPhase 2

See all AEMCOLO clinical trials

US Patents and Regulatory Information for AEMCOLO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Cosmo Technologies AEMCOLO rifamycin TABLET, DELAYED RELEASE;ORAL 210910-001 Nov 16, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Moodys
Merck
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.